Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00817817 | A Study to Determine the Efficacy and Safety of Two Mometasone Dry Powder Inhalers in the Treatment of Asthma (Study P02524) | PHASE3 | COMPLETED | 93 | — | — | Oct 1, 2002 | May 1, 2003 | Aug 15, 2024 | - | — |
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MF | DEVICE | One evening dose of dry powder inhaled MF 400 μg (Multidose device). |
Inclusion Criteria: * Must be \>=18 years of age, of either gender \& of any race. * Must have had a diagnosis of asthma for at least 6 months, characterized by recurrent episode of wheezing, breathlessness, chest tightness \& coughing. * Baseline FEV1 must be \>=55% and \<=85% of predicted at the ...